QRXPF News Alert Qrxpharma Ltd (QRXPF) 0.0080 12/25/2014 23:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Qrxpharma Ltd (QRXPF) 0.0080 $QRXPF

Hemorrhage - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjlpxn/hemorrhage) has announced the addition of the "Hemorrhage - Pipeline Review, H2 2013" report to their offering. 'Hemorrhage - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemorrhage, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemorrhage. Hemorrhage - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - A snapshot of the global therapeutic scenario for Hemorrhage. - A review of the Hemorrhage products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemorrhage pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hemorrhage. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hemorrhage pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Grifols, S.A. - Digna Biotech, S.L. - Thrombotargets Corporation - QRxPharma Limited For more information visit http://www.researchandmarkets.com/research/fjlpxn/hemorrhage

Parkinson's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/7k9xvt/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 169 companies are cited in this text including: - Amicus Therapeutics, Inc. - AstraZeneca PLC - Bial - Portela & Ca, S.A. - Calico LLC - Cardax Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - GlaxoSmithKline plc - GliaCure Inc. - H. Lundbeck A/S - Io Therapeutics, Inc. - Iproteos S.L. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Medeia Therapeutics Ltd. - Motac Neuroscience Ltd - Netherlands Translational Research Center B.V. - nLife Therapeutics, S.L. - Novartis AG - OPKO Health, Inc. - Orion Oyj - Peptron, Inc. - Pfizer Inc. - QR Pharma, Inc. - QRxPharma Limited - Raptor Pharmaceuticals Corp. - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Stelic Institute & Co. - Sumitomo Dainippon Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/7k9xvt/parkinsons
RPTP: 9.34 (+0.56), KNMD: (), OPK: 9.63 (+0.21), PFE: 31.42 (-0.03), AZN: 70.44 (+0.26), GSK: 42.85 (+0.11), FOLD: 7.94 (+0.06), NVS: 93.91 (+0.66)

QRxPharma Provides Feedback On End-of-Review Meeting With The FDA On Moxduo®
PR Newswire - Fri Jul 11, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) today provided feedback on its 9 July End-of-Review (EOR) meeting with the United States Food and Drug Administration (FDA). The meeting was held to discuss the feasibility and requirements for approving Moxduo, an immediate release Dual Opioid®, for the treatment of moderate to severe acute pain.

QRxPharma Announces Board Resignations
PR Newswire - Wed Jul 09, 8:02AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that Chairman, Dr. Peter Farrell and Director, Dr. Gary Pace have resigned from the QRxPharma board effective at 9:50am (AEST) 9 July 2014 prior to commencement of the General Meeting (GM) requisitioned by shareholders associated with Langley Walker. It is expected that Bruce Hancox and Dr. Richard Treagus will be appointed as directors pursuant to resolutions in the requisitioned notice of meeting, with those appointments taking effect from the close of the meeting.

Dystonia - Pipeline Review, H1 2014
M2 - Thu Jun 26, 3:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mgqh87/dystonia) has announced the addition of the "Dystonia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dystonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dystonia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dystonia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dystonia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dystonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Addex Therapeutics - Advicenne Pharma SA - EpiVax, Inc. - Ipsen S.A. - QRxPharma Limited For more information visit http://www.researchandmarkets.com/research/mgqh87/dystonia

Century21.com Is The No. 1 Most Visited Real Estate Franchise Website
PR Newswire - Thu Jan 16, 8:08AM CST
Century 21 Real Estate LLC, the franchisor of the world's largest residential real estate sales organization, announced today that its website - century21.com - has become the No. 1 "most visited" real estate franchise website. According to comScore, Inc., a global leader in digital measurement and analytics, century21.com attracted more unique visitors than any other real estate franchise brand site in every month of 2013. In fact, century21.com holds a commanding lead in the number of unique website visitors in 2013 with 25.3 million for the entire year, which was approximately 10 million unique visitors higher than the next-closest national franchise brand. In a year where the industry average for all real estate sites was a 1% gain in total unique website visitors, CENTURY 21 posted a 49% year-over-year increase.
RLGY: 43.91 (+0.39), SCOR: 47.60 (+0.56)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 34

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 36

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 5

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 70

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 20

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
PAG, HOWL and PSNL Deals Face Fresh Shareholder Checks

Updated Category News Views 60

Three proposed takeovers, three very different headaches, and one familiar question that never gets old: are regular shareholders actually receiving the best available deal? On Nov. 20, 2026, investor-rights law firm Halper Sadeh LLC said it was investigating the proposed transactions involving Penske Automotive Group, Werewolf Therapeutics and Personalis for potential...

Continue Reading
AMP Pushes Debt Wall to 2029 With €1.3B Green Notes

Updated Category News Views 83

A Refinancing With Some Actual Breathing Room Metal cans may be boring, but a debt wall arriving in 2028 is not—and Ardagh Metal Packaging has moved that problem down the road. AMP priced €1.3 billion of senior secured floating-rate green notes on November 20, 2026. The proceeds are earmarked to redeem $600 million of senior secured green notes due in 2028 and €450...

Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps

Updated Category News Views 72

Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...

Continue Reading
Subsplash Builds a Broader Church Software Stack in 2026

Updated Category News Views 54

Church software has spent too many years behaving like a junk drawer, and Subsplash is plainly trying to replace it with one working system. The company used its November 18 Product Event in Dallas to show off releases from 2026 and preview two additions: Communications, due in December, and Subsplash Intelligence, targeted for early 2027. A Serious Push Beyond the Church...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 55

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategies for Maximizing Your Retirement with $1 Million

Updated Category News Views 148

Planning for a Comfortable Retirement with $1 Million Reaching the milestone of having $1 million saved in your IRA as you near your 70th birthday is a commendable accomplishment. However, to make sure this amount lasts throughout your retirement, which could extend over two decades, careful planning is essential. Effectively managing your retirement funds requires a good...

Continue Reading
Wells Fargo Downgrades SailPoint to Equalweight: What It Means

Updated Category News Views 116

Wells Fargo Downgrades SailPoint Technologies Holdings Wells Fargo has recently revised its stance on SailPoint Technologies Holdings (NYSE: SAIL), changing its investment rating from Overweight to Equalweight. Alongside this rating downgrade, the bank has also lowered its price target for the stock from $17 to $15. This shift indicates a more reserved outlook on the...

Continue Reading
Brunswick Exploration's Promising Lithium Recovery Results

Updated Category News Views 120

Promising Phase 1 Metallurgical Results from Brunswick Exploration Brunswick Exploration Inc. (TSX-V: BRW; OTCQB: BRWXF; Frankfurt: 1XQ) has exciting developments regarding its Mirage Project. The Montreal-based mineral exploration company is charting a significant course in extracting lithium through innovative methodologies. Recent preliminary metallurgical results from...

Continue Reading
Enhancing Bone Health: A New Partnership in Australia

Updated Category News Views 174

The Global Healthy Living Foundation Australia (GHLF Australia) forged a partnership with The Bone Bus back then, aiming to pump up bone health access in rural spots where folks were really struggling. This initiative wasn't just some PR stunt; it targeted real issues surrounding osteoporosis that so many older Australians faced. Rural Access: A Tough Nut to Crack Let’s...

Continue Reading
Kotak Securities Revises Target for Larsen & Toubro, Maintains Sell Rating

Updated Category News Views 176

Kotak Securities slammed the brakes on any bullish sentiment around Larsen & Toubro Ltd. (LT:IN) back in late 2024, despite raising their price target from INR3,150 to INR3,380. Now, this sounds like good news on paper—a bit of upward adjustment—but let’s not kid ourselves here. They slapped a Sell rating on it right alongside that shiny new number. What gives?...

Continue Reading